In light of Incyte's epacadostat debacle, NewLink scraps PhIII plans for its own IDO drug
After seeing its shares get dragged down by Incyte’s late-stage debacle, NewLink Genetics is scrapping a PhIII trial for its own IDO drug, raising further questions about the pathway.
It will not initiate the randomization portion of Indigo301, the Ames, IA-based company $NLNK said, a melanoma study that would have evaluated indoximod in combination with checkpoint inhibitors Keytruda or Opdivo in 600 patients. In a press release, NewLink explained the decision was made “in the context of the failure of a competitor’s trial of its enzymatic IDO inhibitor in a similar clinical setting.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.